Newsroom
Investing
Strategy, asset allocation, and how to read the market.
TSMC needs $17.1bn of second-half operating cash to cover a $64bn capex year
TSMC generated $46.914bn of operating cash in the first half of 2026. If cash capex reaches the $64bn ceiling and is measured on the same basis as TSMC's quarterly figures, another $17.086bn from operations would cover it before dividends, but that is a break-even threshold, not a forecast or a verdict on whether the investment will earn an adequate return. [TSMC financial statements](https://investor.tsmc.com/english/encrypt/files/encrypt_file/reports/2026-07/114aaca0fea2050e96b91fffbab9ed04ba09cd92/FS.pdf) [Focus Taiwan](https://focustaiwan.tw/business/202607160019)
The Memory Selloff That Skipped Its Own Target
A report that China's DeepSeek is designing its own AI inference chip barely moved Nvidia, the named target, yet knocked memory makers three to four times harder. Tested against the cross-section, the moves do not sort by high-bandwidth-memory exposure, the one trait a genuine inference-memory scare should hit, which points to a crowded, high-beta cohort shaken out on a 'sell the news' day rather than a real repricing of memory demand.
The $400 Million That Wasn't a Default Wave
HSBC has told clients it will stop financing riskier private-credit funds, and the market read it as Europe's biggest bank fleeing a $3.5 trillion sector as defaults bite. The paper trail says the bulk of the loss traces to one alleged fraud, not a wave of borrower defaults, and that pulling 'back leverage' reprices a financing layer rather than yanking loans out of the real economy. The catch: repricing that layer is not free, and the mid-year results are the tie-breaker.
Vertex Paid $8.8 Billion for Crinetics. Most of the Growth It Bought Is a Drug It Can't Sell Yet.
On July 6, 2026, Vertex agreed to buy Crinetics for about $8.8 billion net of cash, its largest deal ever. Reconstructing Vertex's own peak-sales pitch shows most of the combined revenue potential rides on atumelnant, an unapproved Phase 3 candidate, not on PALSONIFY, the launched acromegaly pill running at roughly $41 million a year. That is where the growth sits, not proof Vertex overpaid: paying up for a pipeline is normal, and the finding is about locating the bet.
